

Immune Provides Financial Information in Response to Nasdaq First North Stockholm

Englewood Cliffs, NJ – October 23, 2017 - Immune Pharmaceuticals Inc. (the "Company") announced today that on October 19, 2017, Nasdaq First North Stockholm (the "Exchange") halted trading in the Company's shares pending the Company's providing public disclosure in Sweden regarding its current financial position.

The Company is a research based biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Currently, the Company has no revenue from operations. The Company intends to obtain revenue in the future from licensing fees, milestone payments, development fees, royalties and/or sales related to the use of its drug candidates or intellectual property for specific therapeutic indications or applications

As disclosed in the Company's Quarterly Report on Form 10-Q filed with the United States Securities and Exchange Commission, as of June 30, 2017, the Company had approximately \$22,000 in cash, a working capital deficit of approximately \$14.1 million and an accumulated deficit of approximately \$104.3 million. The Company has sustained net losses since inception. Net cash used in operating activities was \$4.5 million for the six months ended June 30, 2017.

Since June 30, 2017, the Company executed the following financing transactions:

- On July 7, 2017, the Company, Hercules Capital, Inc. ("Hercules") and certain subsidiaries of the Company, as guarantors, entered into an Assignment Agreement with an accredited investor (the "Investor") whereby Hercules assigned to the Investor the existing amount outstanding under the Loan and Security Agreement between the Company and Hercules dated as of July 29, 2015 (the "Loan Agreement"), as further evidenced by a Secured Term Promissory Note that was issued by the Company to Hercules on July 29, 2015 (the "2015 Note"): the 2015 Note and the Loan Agreement together, (the "Securities"). Additionally, the Company and the Investor entered into an Exchange Agreement whereby the Company issued to the Investor a senior secured convertible promissory note with a principal amount of \$2,974,159 (the "Exchange Note") in exchange for the Securities.
- On August 24, 2017, the Company entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional investors for the sale of \$858,000 in principal amount of original issue discount convertible debentures. The Company obtained proceeds from the offering, before deducting fees and expenses, of \$660,000.
- On October 19, 2017, the Company announced the pricing of an underwritten public offering of units for gross proceeds of \$18,000,000, which excludes underwriting discounts and commissions and offering expenses payable by the Company. The offering is comprised of units, priced at a public offering price of \$1,000 per unit. Each unit consists of one share of Series E Convertible Preferred Stock and 982 warrants (the "Warrants"), each of which entitles the holder to purchase one share of the Company's common stock. The Warrants are initially exercisable at an exercise price of \$1.10 per share and expire 7 years from the date of issuance.

The Company anticipates that it will continue to issue equity and/or debt securities as a source of liquidity, until such time as it generates positive cash flow to support operations. In addition, the Company will seek to divest non-core assets and enter into collaborative agreements to generate cash to support operations. Any future sales of securities to finance operations will dilute existing stockholders' ownership. The Company cannot guarantee when or if it will generate positive cash flow.

Approximately 2.9 million ordinary shares of the Company are listed on the Nasdaq Stockholm exchange. The Company intends to work with the Exchange and the Company's Certified Adviser, Erik Penser Bank, to comply with any additional requests for disclosure and/or information required by the rules of the Exchange.

For further information contact:

Immune Pharmaceuticals Inc.

Elliot Maza, Chief Executive Officer

elliott.maza@immunepharma.com

Tel: Area Code 201.464.2677

The foregoing information is information which Immune Pharmaceuticals Inc. is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the contact person set out above, at 08.00 CET on October 23, 2017.

Immune Pharmaceuticals Inc. is listed at Nasdaq First North Stockholm. Erik Penser Bank is the Company's Certified Adviser.

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other diseases, including atopic dermatitis, immune and inflammatory hepatitis, and asthma.

Safe Harbor Statements Regarding Forward Looking Statements

The statements in this news release made by representatives of Immune relating to matters that are not historical facts, including without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Immune's product candidates and the sufficiency of Immune's cash and other capital resources, the continued development by Immune of bertilimumab or its determination to seek Orphan Drug designation for the pharmaceutical product of bertilimumab are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Immune's ability to

fund such efforts with or without partners. Immune undertakes no obligation to update any of these statements. In addition, there can be no assurance that Immune will successfully complete its anticipated corporate restructuring, or that Immune will be able to reduce expenses, capitalize on strategic alternatives, develop its assets, and generate value for shareholders. Immune may, at any time and for any reason until the proposed spin-off is complete, abandon the spin-off or modify its terms and conditions, or consider competing, alternate or complimentary transactions or offers by third parties at the discretion of Immune's board of directors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Immune's filings with the Securities and Exchange Commission, including those discussed in Immune's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and periodic reports filed on Form 8-K